末梢血管用デバイスの世界市場予測（～2024年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.2.1 MARKETS COVERED 20
1.2.2 REGIONAL COVERAGE 20
1.2.3 YEARS CONSIDERED FOR THE STUDY 21
1.3 CURRENCY 21
1.4 LIMITATIONS 21
1.5 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 SECONDARY DATA 23
2.1.1 KEY DATA FROM SECONDARY SOURCES 23
2.2 PRIMARY DATA 24
2.2.1 KEY DATA FROM PRIMARY SOURCES 25
2.3 MARKET SIZE ESTIMATION 25
2.3.1 BOTTOM-UP APPROACH 26
2.3.2 TOP-DOWN APPROACH 26
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 35
4.1 PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW 35
4.2 NORTH AMERICA: ANGIOPLASTY STENTS MARKET (2018) 36
4.3 GEOGRAPHICAL SNAPSHOT OF THE PERIPHERAL VASCULAR DEVICES MARKET 37
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 39
5.2.1.1 Rapid growth in the geriatric population and the subsequent increase in the prevalence of peripheral vascular diseases 39
5.2.1.2 Product approvals 39
5.2.1.3 Increasing prevalence of diabetes 40
5.2.2 RESTRAINTS 41
5.2.2.1 Product failures and recalls 41
 
5.2.3 OPPORTUNITIES 41
5.2.3.1 Emerging markets 41
5.2.4 CHALLENGES 42
5.2.4.1 Availability of alternative treatments 42
6 ANGIOPLASTY BALLOONS MARKET, BY TYPE 43
6.1 INTRODUCTION 44
6.2 OLD/NORMAL BALLOONS 45
6.2.1 OLD/NORMAL BALLOONS WILL CONTINUE TO DOMINATE THE ANGIOPLASTY BALLOONS MARKET IN 2024 45
6.3 CUTTING AND SCORING BALLOONS 46
6.3.1 CUTTING BALLOONS ARE USED TO TREAT ATHEROSCLEROSIS 46
6.4 DRUG-ELUTING BALLOONS 47
6.4.1 DRUG-ELUTING BALLOONS TO WITNESS THE HIGHEST GROWTH IN THE ANGIOPLASTY BALLOONS MARKET DURING THE FORECAST PERIOD 47
7 ANGIOPLASTY STENTS MARKET, BY TYPE 48
7.1 INTRODUCTION 49
7.2 DRUG-ELUTING STENTS 50
7.2.1 DRUG-ELUTING STENTS TO WITNESS HIGHER ADOPTION PRIMARILY DUE TO THE REDUCED RESTENOSIS RATE ASSOCIATED WITH THESE PRODUCTS 50
7.3 BARE-METAL STENTS 51
7.3.1 INCREASING USE OF DRUG-ELUTING STENTS TO RESTRAIN MARKET GROWTH 51
7.3.2 BARE-METAL STENTS, BY DELIVERY PLATFORM 52
7.3.2.1 Balloon-expandable stents 52
7.3.2.2 Self-expandable stents 53
8 CATHETERS MARKET, BY TYPE 54
8.1 INTRODUCTION 55
8.2 ANGIOGRAPHY CATHETERS 56
8.2.1 ANGIOGRAPHY CATHETERS TO DOMINATE THE CATHETERS MARKET DURING THE FORECAST PERIOD 56
8.3 GUIDING CATHETERS 57
8.3.1 GUIDING CATHETERS TO ACCOUNT FOR THE SECOND-LARGEST SHARE OF THE CATHETERS MARKET DURING THE FORECAST PERIOD 57
8.4 IVUS/OCT CATHETERS 57
8.4.1 IVUS/OCT CATHETERS SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 57
 
9 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE 59
9.1 INTRODUCTION 60
9.2 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS 61
9.2.1 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 61
9.3 THORACIC AORTIC ANEURYSM STENT GRAFTS 62
9.3.1 INCREASING INCIDENCE OF THORACIC AORTIC ANEURYSMS TO DRIVE MARKET GROWTH IN THE COMING YEARS 62
10 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE 63
10.1 INTRODUCTION 64
10.2 RETRIEVABLE FILTERS 65
10.2.1 RETRIEVABLE FILTERS SEGMENT TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 65
10.3 PERMANENT FILTERS 65
10.3.1 RISKS ASSOCIATED WITH PERMANENT FILTERS TO HAMPER THEIR SALES DURING THE FORECAST PERIOD 65
11 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 67
11.1 INTRODUCTION 68
11.2 ATHERECTOMY DEVICES 69
11.2.1 INCREASING INCIDENCE OF ATHEROSCLEROSIS AS A RESULT OF THE RISING GLOBAL PREVALENCE OF OBESITY—A KEY MARKET DRIVER 69
11.3 THROMBECTOMY DEVICES 70
11.3.1 GROWING DVT INCIDENCE TO DRIVE THE ADOPTION OF THROMBECTOMY DEVICES 70
12 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 71
12.1 INTRODUCTION 72
12.2 EMBOLIC PROTECTION DEVICES 72
12.2.1 INCREASING INVESTMENTS IN NEW TECHNOLOGY DEVELOPMENT AND THE GROWING NUMBER OF REGULATORY APPROVALS FOR THESE DEVICES TO DRIVE MARKET GROWTH 72
12.3 CHRONIC TOTAL OCCLUSION (CTO) DEVICES 73
12.3.1 INCREASING INVESTMENTS IN THE DEVELOPMENT OF CTO DEVICES TO DRIVE MARKET GROWTH 73
13 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 75
13.1 INTRODUCTION 76
13.2 GUIDEWIRES 77
13.3 VASCULAR CLOSURE DEVICES 78
13.4 INTRODUCER SHEATHS 79
13.5 BALLOON INFLATION DEVICES 80
 
14 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION 82
14.1 INTRODUCTION 83
14.2 NORTH AMERICA 84
14.2.1 US 88
14.2.1.1 Favorable reimbursement scenario ensures device adoption in the US 88
14.2.2 CANADA 91
14.2.2.1 Rising prevalence of target diseases will drive market growth 91
14.3 EUROPE 95
14.3.1 GERMANY 99
14.3.1.1 Increase in geriatric and obese populations will contribute to device demand 99
14.3.2 FRANCE 102
14.3.2.1 Incidence of PE and DVT will increase, corresponding to growth in France’s geriatric population 102
14.3.3 UK 106
14.3.3.1 Increasing incidence of peripheral vascular diseases to support market growth in the UK 106
14.3.4 SPAIN 109
14.3.4.1 Rising geriatric population to increase the demand for peripheral vascular devices in Spain 109
14.3.5 ITALY 112
14.3.5.1 Increasing health expenditure and rising diabetes prevalence are the major factors driving market growth in Italy 112
14.3.6 REST OF EUROPE 116
14.4 ASIA PACIFIC 120
14.4.1 JAPAN 124
14.4.1.1 Presence of a large geriatric population – A major factor supporting market growth in Japan 124
14.4.2 CHINA 127
14.4.2.1 Growing target patient population in China to drive market growth 127
14.4.3 INDIA 130
14.4.3.1 Increasing prevalence of diabetes to drive the adoption of peripheral vascular devices 130
14.4.4 REST OF ASIA PACIFIC 134
14.5 REST OF THE WORLD 137
14.5.1 LATIN AMERICA 140
14.5.1.1 Growing geriatric population and the subsequent increase in the prevalence of peripheral artery diseases to drive market growth 140
14.5.2 MIDDLE EAST & AFRICA 143
14.5.2.1 Increasing prevalence of diabetes to drive market growth 143
 
15 COMPETITIVE LANDSCAPE 147
15.1 OVERVIEW 147
15.2 MARKET SHARE ANALYSIS, 2017 148
15.3 COMPETITIVE SCENARIO 149
15.3.1 PRODUCT LAUNCHES AND APPROVALS, 2015–2018 149
15.3.2 ACQUISITIONS, 2015–2018 149
15.3.3 AGREEMENTS, 2015–2018 149
15.3.4 EXPANSIONS, 2015–2018 150
15.4 COMPETITIVE LEADERSHIP MAPPING (2017) 150
15.4.1 VENDOR INCLUSION CRITERIA 150
15.4.2 VISIONARY LEADERS 150
15.4.3 INNOVATORS 150
15.4.4 DYNAMIC DIFFERENTIATORS 151
15.4.5 EMERGING COMPANIES 151
15.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2017) 152
15.5.1 PROGRESSIVE COMPANIES 152
15.5.2 STARTING BLOCKS 152
15.5.3 RESPONSIVE COMPANIES 152
15.5.4 DYNAMIC COMPANIES 152
16 COMPANY PROFILES 154
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
16.1 MEDTRONIC 154
16.2 BOSTON SCIENTIFIC CORPORATION 158
16.3 ABBOTT LABORATORIES 162
16.4 BECTON, DICKINSON AND COMPANY 165
16.5 TERUMO CORPORATION 168
16.6 CORDIS (A SUBSIDIARY OF CARDINAL HEALTH, INC.) 171
16.7 B. BRAUN MELSUNGEN AG 174
16.8 IVASCULAR 176
16.9 BIOSENSORS INTERNATIONAL GROUP LTD. 178
16.10 BIOTRONIK 179
16.11 PENUMBRA, INC. 180

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
 
17 APPENDIX 182
17.1 INSIGHTS OF INDUSTRY EXPERTS 182
17.2 DISCUSSION GUIDE 183
17.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 187
17.4 AVAILABLE CUSTOMIZATIONS 189
17.5 RELATED REPORTS 189
17.6 AUTHOR DETAILS 190